The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
immunocore sees institutional investment growth amid mixed analyst ratings
Janus Henderson Group PLC increased its stake in Immunocore to 257,080 shares valued at $16.7 million, while BNP PARIBAS ASSET MANAGEMENT raised its holdings by 16.2% to 397,463 shares worth $13.5 million. Institutional investors own 84.5% of the stock. UBS Group initiated coverage with a "sell" rating and a $24 price target, indicating a potential downside, while other analysts maintain a "Moderate Buy" rating with a consensus target price of $75.17. Immunocore reported a revenue increase of 26.2% year-over-year, with a quarterly earnings per share of ($0.23), surpassing expectations.
global fund giants compete for billions in indian bond etfs
Major ETF providers, including BlackRock and Amundi, are competing for a share of the anticipated $5 billion to $10 billion influx into Indian bonds, following JPMorgan's inclusion of Indian debt in its emerging-market index. This move is expected to significantly boost investment in the sector.